Thomas P. Schnettler - Jun 1, 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Director
Signature: /s/ Thomas P. Schnettler, by Brian McKelligon, as Attorney-in-Fact
Stock symbol: AKYA
Transactions as of: Jun 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/5/2023, 05:37 PM
Previous filing: May 19, 2023
Next filing: Jun 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKYA	Common Stock						0	Jun 1, 2023	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Stock Option (Right to Buy)	Award	$0	+56.3K		$0.00	56.3K	Jun 1, 2023	Common Stock	56.3K	$5.70	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is no longer reporting indirect ownership of shares held by Piper Sandler Merchant Banking Fund II, L.P. as a group of three or more individuals have voting and dispositive control over such shares, with each individual having one vote, and the approval of a majority of such individuals is required to approve an action; therefore, under the so-called "rule of three," no one individual is deemed to have or share beneficial ownership of such shares.
F2	Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.

Content

The Reporting Person is no longer reporting indirect ownership of shares held by Piper Sandler Merchant Banking Fund II, L.P. as a group of three or more individuals have voting and dispositive control over such shares, with each individual having one vote, and the approval of a majority of such individuals is required to approve an action; therefore, under the so-called "rule of three," no one individual is deemed to have or share beneficial ownership of such shares.

Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.